Gruss E.
Hard to Treat Diseases Incorporated - HTDS - Announces: Tubercin Passes Toxicity Trials!
DELRAY BEACH, Fla., Nov 28, 2003 (BUSINESS WIRE) -- Hard to Treat Diseases
Incorporated (Pink Sheets:HTDS) announced today that the spokesperson for the
independent medical group conducting the testing for HTTD (HTDS) has advised
HTTD that Tubercin(R) has passed the toxicity tests required to proceed to the
live cancer trials. Testing Tubercin(R) on live Melanoma, Lung and Breast cancer
cells will begin immediately.
The President and CEO, Mr. Colm J. King, met with the spokesperson of the
medical group at their offices in Oklahoma City. Mr. King was advised that the
tests were conducted under strict FDA (Federal Drug Administration) guidelines.
Full test results will be available at the corporate offices as soon as the
reports and findings are printed.
"These are the most promising results to date regarding Tubercin(R) and we're
looking forward to additional positive results in the near future," stated Mr.
King. "These tests prove that Tubercin(R) is non-toxic and is the first step on
the way to human clinical trials as well as the first positive breakthrough
conducted in the United States with an independent medical group for
Tubercin(R)."
Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated
("HTTD") holds the international marketing rights, except South Korea, to
Tubercin(R), a patented immunostimulant developed for combating Cancer under
medical patent (US Patent 6,274,356). The unique properties unlike other cancer
products are clearly stated in the abstract summary of the patent... "A
carbohydrate complex, which is a mixture of low molecular-weight polysaccharides
of an arabinomannan structure extracted from Mycobacterium tuberculosis, is
highly effective in treating various cancer patients without incurring any
adverse side effects."
Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Securities Act of 1933, as
amended. Those statements include statements regarding the intent, belief or
current expectations of the Company and its management. Such statements reflect
management's current views, are based on certain assumptions and involve risks
and uncertainties. Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not limited to,
our ability to obtain additional financing and access funds from our existing
financing arrangements that will allow us to continue our current and future
operations and whether demand for our product and testing service in domestic
and international markets will continue to expand. The Company undertakes no
obligation to publicly update these forward-looking statements to reflect events
or circumstances that occur after the date hereof or to reflect any change in
the Company's expectations with regard to these forward-looking statements or
the occurrence of unanticipated events.
SOURCE: Hard to Treat Diseases Incorporated
Zurück
